Seattle Genetics, Inc. Highlights ADCETRIS® (Brentuximab Vedotin) Frontline HL and MTCL Clinical Development Programs and Antibody-Drug Conjugate (ADC) Collaborator Data at American Society of Clinical Oncology Annual Meeting

Published: Jun 03, 2013

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

Seattle Genetics, Inc. (Nasdaq: SGEN) today highlighted ongoing clinical development programs for ADCETRIS (brentuximab vedotin) in frontline Hodgkin lymphoma (HL) and mature T-cell lymphoma (MTCL) and progress with collaborator antibody-drug conjugate (ADC) programs that were presented at the 49th Annual Meeting of the American Society of Clinical Oncology being held May 31 – June 4, 2013, in Chicago, IL.

Help employers find you! Check out all the jobs and post your resume.

Back to news